

Elohim Foundation was formerly known as The Carpenter’s Foundation International; a non for profit development organisation founded on the 13th September, 2001 in Abuja –Nigeria and got registered by Cooperate Affairs Commission (CAC) on the 29th of April, 2002.
Goal:
To contribute to the sustainability of the human community through eradication of poverty and impact mitigation of socio-economic challenges and human capacity development
Vision:
To attain sustainable human society
Mission:
To provide social intervention services that addresses the challenges of sustainable human society, through people centred approaches in both urban and rural communities.
Strategic Objectives:
Goal:
Attaining a position of an effective and efficient development organization that is service driven, providing distinctive range of quality humanitarian services, towards a sustainable human society.
Objectives:
a) To provide community based public health awareness, education and laboratory services aimed at increasing access to infection/disease prevention and treatment to the general public.
b) To improve the socio-economic status of the rural and urban poor.
c) To promote green development and peace building practices among community dwellers.
d) To promote a culture of Democratic Governance and transformational leadership in all human society.
e) To promote knowledge and skills acquisition necessary for human and society development in attaining sustainability.
f) To increase Elohim Foundation operational efficiency and effectiveness.
Strategy:
a) Community sensitization, mobilization for medical outreaches and referral services.
b) Entrepreneurship skills/economic development and community capacity programming among women, children and youths.
c) Environmental education, protection and disaster impact mitigation services and humanitarian in emergency among victims and vulnerable communities.
d) Public accountability and citizenship participation programming among citizens and democratic institutions.
e) A mix of creative alternatives involving training, conferences, seminars and social research activities.
f) Constant monitoring, evaluation, accountability and learning processes that will improve the quality of services and ensuring evidence based results at all times.
The Broad rationale for the operations of the organization in all spheres is predicted on the following:
a) That life in general is a costly gift of God, which need be preserved and cherished.
b) That as God’s ambassadors on earth, we are called to complement creation by giving our all towards its sustenance for today and tomorrows generations
c) That human and societal development is a broad band spectrum that requires the input of all sectors, as governments of nations cannot do it alone.
Hepatitis and PWID/harm reduction
11:35 – 11:40
Chair: WHO – Intro and set the scene.
11:40 – 11:55
Co-chair: EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe.
11:55 – 12:00
ID 29: Ema Pos (not yet registered)
Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation.
12:05 – 12:10
ID 152: Brian Conway (Registered in person)
Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.
12:10 – 12:15
ID 212: Jasmine West (not yet registered)
Title: From lived experience to lived expertise: a syndemic approach.
12:15 – 12:20
ID: 299 Mercy Nyakowa (Registered in person)
Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya
12:20 – 12:25
ID: 133 Nalinikanta Rajkumar (Registered in person)
Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?
12:25 – 12:30
Q&A and closing remarks
tHIS
IS
BEN’S
BIG
TEST
effective case finding strategies
Supported by Vir Biotechnology, Inc
During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.
Session Agenda
14:40 – 14:45
Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)
14:45 – 15:05
Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology
15:05 – 15:10
Final remarks and close